Aadi Bioscience Hits New 52-Week High of $3.94, Up 115.52%

Aadi Bioscience, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 3.94 on March 6, 2026. This achievement marks a notable increase from its 52-week low of USD 1.39, reflecting a remarkable one-year performance of 115.52%, significantly outpacing the S&P 500's performance of 17.45%. With a market capitalization of USD 144 million, Aadi Bioscience operates in a competitive industry characterized by rapid innovation and development. The company's financial metrics indicate it is currently loss-making, with a negative return on equity of -9.94% and a debt-to-equity ratio of -1.03. Additionally, the stock has a price-to-book ratio of 0.91, suggesting it is trading below its book value. As Aadi Bioscience continues to navigate the dynamic landscape of pharmaceuticals and biotechnology, this recent price movement underscores its evolving market position and the potential for future developments within the company.